Add like
Add dislike
Add to saved papers

[Treatment results of patients with rectum tumor in a city hospital].

Magyar Sebészet 2017 March
INTRODUCTION: Two hundred and three patients were operated on with rectal malignancy between 2007 and 2014 in our surgical department.

METHODS: Of these, patients who had cancer within 16 cm of the anal verge were included. 73 patients received neoadjuvant treatment and 130 patients were treated with primary resection. The specimens were graded by the Dworak and the Rödel regression score system.

RESULTS: We found strong response in 45 patients and pathologic complete remission in three patients. 5-years survival was compared in the two groups operated between 2007 and 2009. While the overall survival rates were just the same, we can report that response to neoadjuvant therapy is a strong predictor of disease free survival. The incidence of loco-regional recurrence was lower in patients who received neoadjuvant treatment compared to the ones who underwent primary resection. Postoperative complications, incidence of anastomotic leakage were also analysed. We did not find increase in the postoperative complications in the group of patients with neoadjuvant treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app